GlassScriptPhysician profile
Katherine King
NPI 1922332410
$21,477.36
in general payments reported to CMS, 2019-2025
30 companies · $5,474 in 2025
The $5,474 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,965 · 2022: $3,654 · 2023: $5,178 · 2024: $4,207 · 2025: $5,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $2,730 · Travel and Lodging: $305 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,750.95 |
| Consulting Fee | $2,730.00 |
| Travel and Lodging | $304.97 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,549.35 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $3,217.13 | 2021-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $2,316.97 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $1,755.74 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Mdd US Operations, LLC | $1,375.07 | 2022-2025 | Myobloc, Gocovri, Qelbree |
| Neurocrine Biosciences, INC. | $1,156.86 | 2021-2025 | Ingrezza, Ongentys |
| Merz Pharmaceuticals, LLC | $731.29 | 2021-2025 | Xeomin, Inbrija |
| Kyowa Kirin, INC. | $668.01 | 2021-2025 | Nourianz |
| Medtronic, INC. | $532.08 | 2022-2025 | Percept PC Brainsense, Activa PC |
| Ipsen Biopharmaceuticals, INC | $504.23 | 2021-2025 | Dysport |
| Sunovion Pharmaceuticals INC. | $504.00 | 2021-2022 | |
| Pfizer INC. | $356.55 | 2023-2025 | |
| Abbott Laboratories | $329.79 | 2021-2025 | Infinity |
| Acorda Therapeutics, INC | $328.28 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $276.34 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $255.04 | 2022-2023 | Dhivy |
| Lilly USA, LLC | $251.03 | 2021-2024 | Amyvid, Emgality, Kisunla |
| Allergan, INC. | $202.78 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $188.13 | 2022 | |
| Eisai INC. | $172.84 | 2021-2024 | |
| Ucb, INC. | $133.21 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $122.54 | 2022-2025 | |
| Amgen INC. | $111.47 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $95.60 | 2021 | |
| Impel Pharmaceuticals INC. | $83.16 | 2023 | Trudhesa |
| Boston Scientific Corporation | $82.44 | 2024-2025 | General - Dbs |
| Axsome Therapeutics, INC. | $57.09 | 2025 | Symbravo |
| Genentech USA, INC. | $48.72 | 2022 | |
| Impel Pharmaceuticals LLC | $43.02 | 2025 | Trudhesa |
| Biogen, INC. | $28.60 | 2025 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.